Online marktplaats lanceert DataSmart™ platform gebaseerd op blockchain technology

SAN DIEGO–(BUSINESS WIRE)– Scientist.com,  de leidende online marktplaats van de biowetenschap voor uitbesteed onderzoek, maakt vandaag bekend dat het DataSmart^TM  heeft gelanceerd, een platform om de integriteit van gegevens en informatie te waarbogen. DataSmart^TM is gebaseerd op de door Scientist.com ontwikkelde eigen blockchaintechnologie.

“Het vermogen van een blockchain om de integriteit van informatie te waarborgen is de basis voor het gebruik ervan in cryptocurrencies. In biofarmaceutisch onderzoek hebben we de blockchain-technologie nodig voor het controleren en valideren van de onderzoekgegevens en om de integriteit daarvan te waarborgen”, stelt Chris Petersen, CTO en oprichter. “Onze nieuwe DataSmart^TM-platform stelt farmaceutische en biotechbedrijven in staat om aan te tonen dat kritische leveranciersinformatie en belangrijke onderzoeksgegevens niet zijn gemanipuleerd en dus onveranderd blijven.”

Scientist.com Creates Blockchain Solution That Ensures Marketplace Data Integrity

Online marketplace launches DataSmart™ platform based on blockchain technology

SAN DIEGO–(BUSINESS WIRE)– Scientist.com, the life science industry’s leading online marketplace for outsourced research, announced today that it has launched DataSmart^TM, a platform to ensure data and information integrity. DataSmart^TM is based on proprietary blockchain technology developed by Scientist.com.

“Blockchain’s ability to ensure the integrity of information is the basis of its use in cryptocurrencies. In biopharma research we need blockchain technology to verify and validate the supply chain and to ensure the integrity of research data,” stated Chris Petersen, CTO and Founder. “Our new DataSmart^TM platform enables pharmaceutical and biotech companies to demonstrate that critical supplier information and important research data has not been tampered with and remains unaltered.”

Much of the data created during late-stage preclinical and clinical phases of drug development is submitted electronically to regulators prior to drug approval. Biopharma companies need to prove to regulators that the data has not been tampered with since it was first obtained. Within the biopharma industry, late-stage preclinical and clinical research is subject to the strict guidelines of 21CFR Part 11, under which electronic records are considered trustworthy and equivalent to paper records.

“The cost and time spent adhering to 21CFR Part 11 has made it prohibitive to ensure data integrity at earlier stages of the drug discovery and development process,” commented Kevin Lustig, CEO and Founder. “Our new DataSmart^TM platform makes it possible to extend data integrity protections throughout the entire drug research process, from concept to clinic and beyond.”

About Scientist.com

Scientist.com is the world’s leading marketplace for outsourced research. The marketplace simplifies the entire research sourcing process, saving time and money and providing access to the latest innovative tools and technologies while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, VWR and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised more than $33 million from Leerink Transformation Partners, 5AM Ventures, Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo among others. Visit scientist.com to learn more.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180430005047/en/

Contacts

Scientist.com
Sean Preci
Director of Communications
+1 858-455-1300 ext. 401
marketing@scientist.com